-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Calumet, Raises Price Target to $24

Benzinga·01/30/2026 17:40:57
Listen to the news
Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Buy and raises the price target from $20 to $24.